Beacon Therapeutics raised $170m in Series B funding led by Forbion, joined by TCGX, Advent Life Sciences, Syncona, Oxford Science Enterprises.

United Kingdom Netherlands United States 30 June 2024
Share:
Total investments received (USD): 366.25m

Related deals

Top